Phase II Trial

"organ preservation in rectal adenocarcinoma: a phase ii randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.", by Smith JJ, Chow OS, Gollub MJ, Nash GM, Temple LK, Weiser MR, Guillem JG, Paty PB, Avila K, Garcia-Aguilar J, Rectal Cancer Consorti. Fig1: Trial schema. MSKCC-based multi-institutional, Phase II trial schema underway to test the feasibility of incorporating a NOM approach to the multimodality treatment of rectal cancer. This study will evaluate the 3-year DFS in LARC...

Investigators prepare on carrying out a multicenter randomized, double-blind, placebo controlled Phase II medical trial using a futility style. The research would consist of acetylcholine receptor antibody positive generalised MG topics. This research study provides a special possibility to examine both medicine and disease mechanisms due to the fact that unlike many other autoimmune diseases in which rituximab has been used, MG manages the examination of antigen-specific components that join the immunopathology of the disease, particularly autoantibodies, autoantibody-producing B cells, and antigen-specific T cells. This work will further our understanding of MG immunopathology and it represents the primary step toward getting a more complete understanding of the immune mechanisms underlying treatment of MG with rituximab leading to new means to treat the disease. The specific purpose of this research study is to identify whether rituximab is a efficient and safe treatment for topics with MG. Prednisone only: Prednisone dose need to be at least 15mg/day, and the dose of prednisone have to have been steady for at least 4 weeks before the standard browse through. A breast CT or MRI to examine for thymoma has to be finished as part of prescreening. Males and female of reproductive potential have to accept use an appropriate method of contraception throughout treatment and for twelve months after completion of therapy. Subjects who have been medicated with immunosuppressive drugs not noted in incorporation # 5 within the last 8 weeks before the baseline browse through 7. Subjects that have obtained IVIg or PLEX therapy within the last 4 weeks prior to the baseline visit.

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

** If you believe that content on the Plex is summarised improperly, please, contact us, and we will get rid of it quickly; please, send an email with a brief explanation.